Chimerix, Inc. Presents at Annual EBMT Meeting: Antiviral Activity of CMX001 in Patients With Life-Threatening Viral Infections
4/29/2013 11:36:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DURHAM, N.C., April 29, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the presentation of the first clinical outcomes data on the use of CMX001 in patients with life-threatening infection with adenovirus (AdV), a disease with no approved therapy. The data were presented at the European Group for Blood and Marrow Transplantation's (EBMT) Annual Meeting held April 7 - 10 in London, England. CMX001 is an investigational oral nucleotide analog lipid-conjugate that has a broad spectrum of antiviral activity against double-stranded DNA (dsDNA) viruses.
Help employers find you! Check out all the jobs and post your resume.
comments powered by